CIK 0000730272
- Large accelerated filer
REPLIGEN CORP
Sign in to watch- Ticker
- RGEN
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 042729386
- Phone
- +1 781-449-9560
- Business address
- 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM, MA, 02453
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $4,976,580
- in 4 filings, $5.0M under 10b5-1 plans
Net −$4,976,580. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-10-29 | BARTHELEMY NICOLAS Director | Sale | −360 | $288.19 | $104K | 1,547 |
| 2021-10-29 | BARTHELEMY NICOLAS Director | Exercise or conversion · Stock Option (Right to Buy) | +1,285 | 0 | ||
| 2021-09-14 | DAWES KAREN A Director | Sale | −13 | $290.02 | $4K | 93,908 |
| 2021-09-14 | DAWES KAREN A Director | Sale | −25 | $292.34 | $7K | 93,883 |
| 2021-09-14 | DAWES KAREN A Director | Sale | −101 | $294.06 | $30K | 93,782 |
| 2021-09-14 | DAWES KAREN A Director | Sale | −108 | $295.02 | $32K | 93,674 |
| 2021-09-14 | DAWES KAREN A Director | Sale | −27 | $295.82 | $8K | 93,647 |
| 2021-09-09 | Hunt Anthony Chief Executive Officer | Exercise or conversion | +25,000 | $32.40 | $810K | 214,495 |
| 2021-09-09 | Hunt Anthony Chief Executive Officer | Sale | −8,536 | $294.22 | $2.5M | 205,959 |
| 2021-09-09 | Hunt Anthony Chief Executive Officer | Sale | −14,825 | $294.90 | $4.4M | 191,134 |
| 2021-09-09 | Hunt Anthony Chief Executive Officer | Sale | −1,631 | $296.09 | $483K | 189,503 |
| 2021-09-09 | Hunt Anthony Chief Executive Officer | Sale | −8 | $296.58 | $2K | 189,495 |
| 2021-09-09 | Hunt Anthony Chief Executive Officer | Exercise or conversion · Stock Option (Right to Buy) | +25,000 | 25,154 | ||
| 2021-09-01 | Gebski Christine | Sale | −3,377 | $285.33 | $964K | 33,318 |
| 2021-09-01 | DAWES KAREN A Director | Exercise or conversion | −3,459 | $38.76 | $134K | 97,380 |
| 2021-09-01 | DAWES KAREN A Director | Sale | −239 | $280.27 | $67K | 97,141 |
| 2021-09-01 | DAWES KAREN A Director | Sale | −196 | $281.68 | $55K | 96,945 |
| 2021-09-01 | DAWES KAREN A Director | Sale | −405 | $282.53 | $114K | 96,540 |
| 2021-09-01 | DAWES KAREN A Director | Sale | −661 | $283.56 | $187K | 95,879 |
| 2021-09-01 | DAWES KAREN A Director | Sale | −1,107 | $284.64 | $315K | 94,772 |
Page 25 of 42 · 832 trades